In a large analysis of prostate cancer patients treated internationally across 12 randomized trials, research from UCLA Jonsson Comprehensive Cancer Center suggests that it is almost universally optimal for men to receive androgen deprivation therapy during and after radiation therapy, rather than before and during RT.
GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.
